Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology - United States
doi 10.1002/ajh.25659
Full Text
Open PDFAbstract
Available in full text
Categories
Date
November 6, 2019
Authors
Publisher
Wiley